Google
LAB 株価分析 — STANDARD BIOTOOLS INC (Healthcare >> Medical Devices)
LAB に関するよくある質問
LABのPER（株価収益率）は？
STANDARD BIOTOOLS INC（LAB）は現在PER 18.22倍で取引されています。
LABのROE（自己資本利益率）は？
STANDARD BIOTOOLS INCのROEは-16.77%です。
LABの配当利回りは？
STANDARD BIOTOOLS INCの配当利回りは0.00%です。
LABの品質スコア（Quality Score）は？
当社のAIはLABの総合財務品質を100点中38点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
LABは今が買い時ですか？
当社AIのタイミングスコアは100点中50点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
LABはどのセクターに属しますか？
STANDARD BIOTOOLS INCはHealthcare >> Medical Devicesセクターに分類されます（NASDAQ市場）
LAB AI Analysis Summary
Our AI summary for LAB: STANDARD BIOTOOLS INC (NASDAQ), Healthcare >> Medical Devices sector. The stock currently trades at a P/E of 18.22, ROE of -16.77%, a dividend yield of 0.00%. Its financial Quality Score stands at 38/100 — fundamentals below the market average. The AI Timing Score is 50/100 — technical signals are mixed; watch for a clearer trend. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 0.87
Price
-0.03
(-3.27%)
Day Change
|
|
|---|
LAB, ファンダメンタルスコアはnot good ( ファンダメンタル = 38) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
ROAがROEに比べて低い
ROAの伸びが低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not quite good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 94 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 0.87 |
| PBV / Sector |
0.63 / -101.57
GREAT
|
| Earning Per Share | -0.23 |
| PE / Sector |
18.22 / 31.23
|
| PEG or PE/Growth / Sector |
-0.32 / 0.40
|
| Average 1M Daily Value |
2.02 M
GREAT
|
| Average 1W Daily Value |
2.32 M
GREAT
|
| Timing Factors |
|
57% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
56% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 08:00:06 |
| Symbol | LAB |
| Name | STANDARD BIOTOOLS INC |
| Sector | Healthcare >> Medical Devices |
| Market | NASDAQ |
| Listed Shares | 391.46 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 351.26 / 20,104.97 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 50 Milk Street, Boston, MA, United States, 02109
Phone: 650 266 6000
Website: https://www.standardbio.com
Employees: 385
Sector: Healthcare >> Medical Devices
Description: Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Medical Devices
Click a bubble to view stock details · Bubble size represents market capitalization share
